Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Conditions:   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory High Risk Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Therapy-Related Myelodysplastic Syndrome Interventions:   Drug: Ibrutinib;   Drug: Lenalidomide Sponsors:   University of California, Davis;   Pharmacyclics LLC.;   Celgene;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Hemophagocytic lymphohistiocytosis (HLH) is a rare disease resulting in clinical and biochemical manifestations of extreme inflammation. Myelodysplastic syndrome (MDS) represents a heterogenous group of clonal hematopoietic disorders. The development of MDS is common in children with trisomy of chromosome 8. Here, we report a fatal case of 8-year-old girl who was admitted to the emergency department with status epilepticus, and later diagnosed with HLH associated with MDS and trisomy of chromosome 8. We believe this is the first reported case of HLH associated with MDS and trisomy 8 in a pediatric patient.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
SUMMARY Granulocytic sarcoma also called myeloid sarcoma is an extramedullary tumour of immature granulocytic cells. It is a rare entity, and mostly accompanied by acute myeloid leukaemia. It is observed during the course of myeloproliferative disorders especially in chronic myeloid leukaemia and myelodysplastic syndromes. Here, we report a case of a 60-year-old male with past history of myelofibrosis admitted to the emergency room due ulceronecrotic lesions, fever and dysphagia. We emphasize the importance of recognizing this entity and its severity.RESUMO O sarcoma granuloc ítico, também chamado de sarcoma ...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
SUMMARY Granulocytic sarcoma also called myeloid sarcoma is an extramedullary tumour of immature granulocytic cells. It is a rare entity, and mostly accompanied by acute myeloid leukaemia. It is observed during the course of myeloproliferative disorders especially in chronic myeloid leukaemia and myelodysplastic syndromes. Here, we report a case of a 60-year-old male with past history of myelofibrosis admitted to the emergency room due ulceronecrotic lesions, fever and dysphagia. We emphasize the importance of recognizing this entity and its severity.RESUMO O sarcoma granuloc ítico, também chamado de sarcoma ...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
In this month's installment ofAsk the PI,ONCOLOGY spoke with two authors of the study, Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
CONCLUSION: Sweet's syndrome is a rare adverse effect of G-CSF. PMID: 30551891 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome, Published online: 16 December 2018; doi:10.1038/s41375-018-0312-9Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Source: Leukemia - Category: Hematology Authors: Source Type: research
Authors: Ding WJ, Yang Y, Chen ZX, Wang YY, Dong WL, Cen JN, Qi XF, Jiang F, Chen SN Abstract Previous studies on the pathogenesis of myelodysplastic syndrome (MDS) have identified multiple associated gene mutations, including mutations of tetmethylcytosinedioxygenase 2, isocitrate dehydrogenase [NADP(+)] 1 cytosolic, isocitrate dehydrogenase [NADP(+)] 2 mitochondrial and additional sex combs like 1 transcriptional regulator, all of which may be considered epigenetic regulators. Furthermore, mutations of RAS type GTPase family genes have been identified in 10-15% patients with MDS. The authors' previous study on th...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
The search for the optimal conditioning regimen prior to allogeneic hematopoietic stem cell transplant (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been ongoing for decades.[1, 2] Early conditioning regimens consisted of high-dose chemotherapy and radiation, now characterized as myeloablative conditioning (MAC), to achieve the aspired outcome of eliminating malignant disease with concomitant restoration of normal hematopoiesis. With experience and improved understanding of the graft-versus-leukemia effect, investigators began to lower the intensity of conditioning regimens.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Aziz Nazha MD of Cleveland Clinic discusses using Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning at ASH 2018 Author: ASHReport Added: 12/14/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Aziz Nazha MD of Cleveland Clinic discusses the overview of his study of A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplast... Author: ASHReport Added: 12/14/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Myelodysplastic Syndrome | Revlimid